Axsome Therapeutics (AXSM) EBIT Margin (2022 - 2026)
Axsome Therapeutics' (AXSM) quarterly EBIT Margin came in at 33.14% in Q1 2026, up 1378.0% year-on-year from 2.24% in Q1 2025, and down 164.1% quarter-over-quarter from 51.7% in Q4 2025.
Axsome Therapeutics (AXSM) EBIT Margin (2022 - 2026) Analysis & Trends
Axsome Therapeutics has disclosed EBIT Margin across 5 years of filings, most recently posting 33.14% for Q1 2026.
- EBIT Margin for Q1 2026 came in at 33.14%, up 1378.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.33% (up 7977.0% YoY), and the FY2025 annual result was 6.03%, up 6672.0% from the prior year.
- EBIT Margin came in at 33.14% for Q1 2026 at Axsome Therapeutics, down from 51.7% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 51.7% in Q4 2025 to a low of 14523.4% in Q4 2024.
- The 5-year median for EBIT Margin is 89.62% (2024), against an average of 1010.94%.
- Across the five-year window, EBIT Margin tumbled 1438601 bps in 2024 and surged 1457510 bps in 2025, its largest moves.
- Axsome Therapeutics' EBIT Margin stood at 245.86% in 2022, then jumped by 44 bps to 137.39% in 2023, then tumbled by 10471 bps to 14523.4% in 2024, then soared by 100 bps to 51.7% in 2025, then sank by 164 bps to 33.14% in 2026.
- The last three EBIT Margin figures came in at 33.14% (Q1 2026), 51.7% (Q4 2025), and 26.97% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Axsome Therapeutics | 13.07 Bn | 12.76 Bn | 176.48 Mn | -33.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.14% |
| Dec 31, 2025 | 51.70% |
| Sep 30, 2025 | -26.97% |
| Jun 30, 2025 | -24.47% |
| Mar 31, 2025 | -46.91% |
| Dec 31, 2024 | -14,523.40% |
| Sep 30, 2024 | -59.78% |
| Jun 30, 2024 | -89.54% |
| Mar 31, 2024 | -89.70% |
| Dec 31, 2023 | -137.39% |
| Sep 30, 2023 | -107.49% |
| Jun 30, 2023 | -139.31% |
| Mar 31, 2023 | -6.74% |
| Dec 31, 2022 | -245.86% |
| Sep 30, 2022 | -251.76% |
| Jun 30, 2022 | -444.23% |